Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06441890 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

Study acronym: BRE-10
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Start date changed from estimate of Jul 2024 to Dec 5, 2024v4
  3. Start date: Jun 2024 to Jul 2024v3
  4. Trial status: Not Yet Recruiting to Recruitingv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care
Trial Details
NCT Number NCT06441890
Lead Sponsor University of Illinois at Chicago
Conditions Breast Cancer, HER2-positive Breast Cancer
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov